Related Experiment Video
Updated: Mar 1, 2026
Fecal Microbiota Transplantation via Colonoscopy for Recurrent C. difficile Infection
Published on: December 8, 2014
Fecal Microbiota Transplantation: From Clostridium difficile to Inflammatory Bowel Disease
Robert J Gianotti1, Alan C Moss1
1Dr Gianotti is a gastroenterology fellow and Dr Moss is an associate professor of medicine and attending gastroenterologist at Beth Israel Deaconess Medical Center and Harvard Medical School in Boston, Massachusetts.
Abstract:
Fecal microbiota transplantation (FMT) has evolved from a case report in the medical literature to the basis of major innovations in the treatment of Clostridium difficile infection (CDI) and, potentially, inflammatory bowel disease (IBD). In the clinical setting, FMT was noted to significantly lower the risk of recurrent CDI, likely by increasing microbial diversity and altering the metabolic environment in the intestinal tract of recipients. In parallel, advances in the ability to quantify and characterize microbial communities in fecal samples led to the association of IBD with a state of intestinal dysbiosis. Consequently, a number of case series and randomized, controlled trials have evaluated FMT in treating active ulcerative colitis or Crohn's disease. Unlike in CDI, the efficacy of FMT in the treatment of IBD appears to be influenced by a number of factors, including donor microbial profiles, inflammatory burden, and the microbial diversity of the recipient. The therapeutic potential of the microbiome has led to a number of biotechnology and pharmaceutical companies isolating specific strains from healthy stool for use as targeted therapies for IBD in clinical trials. Ongoing studies are likely to determine the missing link between the efficacy of FMT and its impact on microbial communities and mucosal inflammation.
Insights
Fecal microbiota transplantation (FMT) effectively treats recurrent Clostridium difficile infection (CDI) by restoring gut microbial diversity. Its efficacy for inflammatory bowel disease (IBD) is being investigated, with factors like donor and recipient microbial profiles influencing outcomes.
Area of Science:
- Gastroenterology
- Microbiology
- Immunology
Background:
- Fecal microbiota transplantation (FMT) has emerged as a significant therapeutic strategy.
- Initially recognized for treating Clostridium difficile infection (CDI), its potential in inflammatory bowel disease (IBD) is under investigation.
- IBD is associated with intestinal dysbiosis, prompting research into microbiome-based therapies.
Purpose of the Study:
- To review the evolution and application of FMT in treating CDI and IBD.
- To explore the factors influencing FMT efficacy in IBD patients.
- To highlight ongoing research into microbiome-targeted therapies for IBD.
Main Methods:
- Review of clinical case reports, series, and randomized controlled trials evaluating FMT for CDI and IBD.
- Analysis of factors affecting FMT success, including microbial diversity, donor characteristics, and recipient inflammation.
- Discussion of current research on isolating specific microbial strains for targeted IBD therapies.
Main Results:
- FMT significantly reduces recurrent CDI by enhancing gut microbial diversity and altering the intestinal metabolic environment.
- FMT's efficacy in IBD treatment is variable and influenced by donor microbial profiles, recipient's inflammatory burden, and baseline microbial diversity.
- Biotechnology companies are developing targeted microbial therapies for IBD based on findings from FMT research.
Conclusions:
- FMT is a proven treatment for recurrent CDI and shows promise for IBD.
- Further research is needed to elucidate the mechanisms linking FMT, microbial communities, and mucosal inflammation in IBD.
- Understanding these mechanisms will optimize microbiome-based therapeutic strategies for IBD.
Related Concept Videos
01:21Inflammatory Bowel Disease V: Surgical Management
Here are some common surgical interventions for IBD:
01:30Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
01:30Inflammatory Bowel Disease II: Crohn's Disease
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
01:21Drugs for Treatment of Constipation-Predominant IBS
01:17Drugs for Treatment of Diarrhea-Predominant IBS
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...